Sold Put x10 for IMGN

ImmunoGen Stock Soars On Positive Data From Ovarian Cancer Drug Trial ImmunoGen said the data would be submitted to the U.S. Food & Drug Administration as party of the agency's' Biologics License Application process in the first quarter of next year.

Positive news for IMGN. Should not be a problem for them to stay above 5, for the next 17 days. However to play safe, I took a SP of 4.